Compare RDNT & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDNT | BLCO |
|---|---|---|
| Founded | 1985 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Ophthalmic Goods |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 6.0B |
| IPO Year | 1986 | 2022 |
| Metric | RDNT | BLCO |
|---|---|---|
| Price | $77.71 | $17.17 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 14 |
| Target Price | ★ $83.60 | $17.31 |
| AVG Volume (30 Days) | ★ 1.0M | 352.7K |
| Earning Date | 11-09-2025 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,969,599,000.00 | ★ $4,976,000,000.00 |
| Revenue This Year | $11.77 | $8.06 |
| Revenue Next Year | $10.76 | $5.79 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.09 | 6.23 |
| 52 Week Low | $45.00 | $10.45 |
| 52 Week High | $85.84 | $18.34 |
| Indicator | RDNT | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 55.94 | 58.18 |
| Support Level | $70.31 | $16.22 |
| Resistance Level | $73.52 | $17.26 |
| Average True Range (ATR) | 3.00 | 0.34 |
| MACD | 0.36 | -0.06 |
| Stochastic Oscillator | 92.67 | 83.97 |
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and fluoroscopy. The Digital Health segment develops and deploys clinical applications to enhance the interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.